Q3 EPS Forecast for PDS Biotechnology Boosted by Analyst

Key Points

• HC Wainwright increased its Q3 2025 earnings per share forecast for PDS Biotechnology from ($0.26) to ($0.25), while maintaining a "Buy" rating and a price target of $13.00.
• PDS Biotechnology’s stock rose 3.4% to a trading price of $1.20, with a market capitalization of $54.85 million.
• Institutional investors hold approximately 26.84% of PDS Biotechnology’s stock, with significant recent purchases by firms like Raymond James and Two Sigma Investments.

PDS Biotechnology Corporation (NASDAQ:PDSB - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of PDS Biotechnology in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.25) per share for the quarter, up from their prior estimate of ($0.26). HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology's FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($0.83) EPS.

Separately, Wall Street Zen lowered shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th.

PDS Biotechnology Stock Up 3.4%

PDSB stock opened at $1.20 on Friday. The firm's 50-day moving average is $1.33 and its two-hundred day moving average is $1.32. The company has a market capitalization of $54.85 million, a price-to-earnings ratio of -1.30 and a beta of 0.95. PDS Biotechnology has a 52 week low of $0.85 and a 52 week high of $4.29. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of 0.29.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in shares of PDS Biotechnology in the 4th quarter worth approximately $26,000. Jane Street Group LLC acquired a new position in PDS Biotechnology in the fourth quarter worth approximately $58,000. Marshall Wace LLP increased its holdings in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock valued at $64,000 after buying an additional 10,837 shares in the last quarter. Tempus Wealth Planning LLC lifted its position in shares of PDS Biotechnology by 154.3% during the 2nd quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company's stock valued at $64,000 after acquiring an additional 29,000 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock worth $107,000 after acquiring an additional 48,132 shares in the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.